-
Je něco špatně v tomto záznamu ?
Significant change in ZAP-70 expression during the course of chronic lymphocytic leukemia
V. Vroblova, F. Vrbacky, M. Hrudkova, K. Jankovicova, D. Schmitzova, J. Maly, J. Krejsek, L. Smolej,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Wiley Online Library (archiv)
od 1997-01-01 do 2012-12-31
- MeSH
- chronická lymfatická leukemie enzymologie etiologie MeSH
- dospělí MeSH
- geny pro těžké řetězce imunoglobulinů MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- nádorové biomarkery krev MeSH
- pilotní projekty MeSH
- progrese nemoci MeSH
- protein-tyrosinkináza ZAP-70 krev MeSH
- recidiva MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
INTRODUCTION: It is widely accepted that expression of ZAP-70 in chronic lymphocytic leukemia (CLL) remains stable in time. However, data supporting this notion are surprisingly scarce. Therefore, we assessed expression of ZAP-70 in serial samples taken during the course of the disease. PATIENTS AND METHODS: We studied 44 patients with CLL diagnosed according to NCI-WG criteria (34 men, 10 women, median age 62, range, 36-81). A total of 104 samples were examined; all patients had at least two measurements. Median interval between the first and the second sample was 13 months (range, 2-36). ZAP-70 expression was detected by flow cytometry using phycoerythrin-conjugated monoclonal antibody clone 1E7.2 and negative isotype control. Twenty percent of positive cells were considered as the threshold of positivity. RESULTS: Significant change in ZAP-70 expression (i.e. from positivity to negativity and vice versa) was detected in 15/44 patients (34%). Interestingly, 7/8 patients whose ZAP-70 expression converted to positivity had unmutated IgVH genes. In addition, the conversion was accompanied by clinical progression or relapse in all but one patient. On the other hand, 5/7 patients with loss of ZAP-70 had stable clinical course. One patient became ZAP-70-negative during treatment with prednisone for autoimmune hemolytic anemia. CONCLUSIONS: In contrast to commonly accepted opinion, significant change in ZAP-70 expression in time was detected in a substantial proportion of our patients with CLL. While the conversion to ZAP-70 negativity was found predominantly in patients with stable disease, change to positivity was typical in patients with unmutated IgVH genes at the time of progression or relapse. Based on our pilot results, repeated assessment of ZAP-70 expression might be especially useful at the time of progression or relapse in patients who were initially ZAP-70-negative.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025939
- 003
- CZ-PrNML
- 005
- 20200227142611.0
- 007
- ta
- 008
- 120817s2010 enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1111/j.1600-0609.2010.01425.x $2 doi
- 035 __
- $a (PubMed)20132303
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vroblová, Vladimíra $7 xx0104044 $u Institute of Clinical Immunology and Allergology, Charles University in Prague, School of Medicine and University Hospital in Hradec Kralove, Czech Republic. vroblvla@fnhk.cz
- 245 10
- $a Significant change in ZAP-70 expression during the course of chronic lymphocytic leukemia / $c V. Vroblova, F. Vrbacky, M. Hrudkova, K. Jankovicova, D. Schmitzova, J. Maly, J. Krejsek, L. Smolej,
- 520 9_
- $a INTRODUCTION: It is widely accepted that expression of ZAP-70 in chronic lymphocytic leukemia (CLL) remains stable in time. However, data supporting this notion are surprisingly scarce. Therefore, we assessed expression of ZAP-70 in serial samples taken during the course of the disease. PATIENTS AND METHODS: We studied 44 patients with CLL diagnosed according to NCI-WG criteria (34 men, 10 women, median age 62, range, 36-81). A total of 104 samples were examined; all patients had at least two measurements. Median interval between the first and the second sample was 13 months (range, 2-36). ZAP-70 expression was detected by flow cytometry using phycoerythrin-conjugated monoclonal antibody clone 1E7.2 and negative isotype control. Twenty percent of positive cells were considered as the threshold of positivity. RESULTS: Significant change in ZAP-70 expression (i.e. from positivity to negativity and vice versa) was detected in 15/44 patients (34%). Interestingly, 7/8 patients whose ZAP-70 expression converted to positivity had unmutated IgVH genes. In addition, the conversion was accompanied by clinical progression or relapse in all but one patient. On the other hand, 5/7 patients with loss of ZAP-70 had stable clinical course. One patient became ZAP-70-negative during treatment with prednisone for autoimmune hemolytic anemia. CONCLUSIONS: In contrast to commonly accepted opinion, significant change in ZAP-70 expression in time was detected in a substantial proportion of our patients with CLL. While the conversion to ZAP-70 negativity was found predominantly in patients with stable disease, change to positivity was typical in patients with unmutated IgVH genes at the time of progression or relapse. Based on our pilot results, repeated assessment of ZAP-70 expression might be especially useful at the time of progression or relapse in patients who were initially ZAP-70-negative.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a geny pro těžké řetězce imunoglobulinů $7 D050438
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x enzymologie $x etiologie $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 650 _2
- $a protein-tyrosinkináza ZAP-70 $x krev $7 D051746
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1#
- $a Vrbacký, Filip. $7 xx0230451
- 700 1_
- $a Motyčková, Monika $7 xx0241598
- 700 1_
- $a Jankovičová, Karolína $7 stk2008428938
- 700 1_
- $a Schmitzová, Daniela $7 xx0128892
- 700 1_
- $a Malý, Jaroslav, $d 1946- $7 nlk19990073524
- 700 1_
- $a Krejsek, Jan, $d 1958- $7 nlk19990073429
- 700 1_
- $a Smolej, Lukáš $7 xx0101489
- 773 0_
- $w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 84, č. 6 (2010), s. 513-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20132303 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20200227143021 $b ABA008
- 999 __
- $a ok $b bmc $g 947981 $s 783285
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 84 $c 6 $d 513-7 $e 20100209 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
- LZP __
- $a Pubmed-20120817/10/03